

Adrenal Crisis Management Market Forecasts to 2032 – Global Analysis By Treatment Type (Glucocorticoid Therapy, Mineralocorticoid Therapy, Fluid & Electrolyte Replacement Therapy and Adjunctive Therapies), Route of Administration (Intravenous, Intramuscular, Oral and Subcutaneous), Patient Group, Distribution Channel, End User and By Geography

<https://marketpublishers.com/r/AA4F37ED46F2EN.html>

Date: September 2025

Pages: 200

Price: US\$ 4,150.00 (Single User License)

ID: AA4F37ED46F2EN

Abstracts

According to Statistics MRC, the Global Adrenal Crisis Management Market is accounted for \$2.6 billion in 2025 and is expected to reach \$4.4 billion by 2032 growing at a CAGR of 7.5% during the forecast period. Adrenal crisis management involves the immediate administration of intravenous or intramuscular hydrocortisone, followed by rapid fluid resuscitation using isotonic saline. It is a critical protocol for patients with adrenal insufficiency facing acute stressors such as infection, trauma, or surgery. Timely intervention prevents shock, organ failure, and death. Continued hydrocortisone dosing and endocrinologist oversight are essential until full clinical recovery is achieved.

According to the National Institutes of Health (NIH), adrenal insufficiency, the primary risk factor for adrenal crisis, has a prevalence of approximately 110-144 cases per million population.

Market Dynamics:

Driver:

Rising prevalence of autoimmune disorders

The escalating incidence of autoimmune conditions such as Addison's disease, congenital adrenal hyperplasia, and primary adrenal insufficiency significantly drives the adrenal crisis management market expansion. Improved diagnostic capabilities and enhanced awareness among healthcare professionals contribute to earlier detection rates. The growing geriatric population, particularly susceptible to endocrine disorders, further amplifies market demand. Moreover, lifestyle factors, including chronic stress, environmental toxins, and dietary changes, have been linked to increased autoimmune disorder prevalence. This epidemiological trend necessitates robust therapeutic interventions and emergency management protocols, thereby creating substantial market opportunities for pharmaceutical companies and medical device manufacturers specializing in adrenal crisis prevention and treatment solutions.

Restraint:

High cost of treatment

Emergency hydrocortisone injections, continuous hormone replacement therapy, and specialized monitoring equipment require considerable healthcare expenditure. The chronic nature of adrenal insufficiency demands lifelong treatment regimens, creating cumulative cost pressures for patients and healthcare systems. Moreover, limited insurance coverage for certain therapeutic options and diagnostic procedures exacerbates affordability challenges. The economic strain is particularly pronounced in developing regions where healthcare infrastructure and reimbursement policies remain inadequate, potentially limiting market penetration and adoption of advanced adrenal crisis management solutions across diverse patient populations.

Opportunity:

Digital health solutions for patient monitoring and adherence

Wearable devices equipped with cortisol monitoring capabilities enable real-time physiological tracking, facilitating proactive crisis prevention. Smartphone applications provide medication reminders, stress level monitoring, and emergency response protocols, improving patient outcomes. Telemedicine platforms connect patients with endocrinologists for remote consultations and dosage adjustments. Moreover, artificial intelligence algorithms can predict crisis episodes based on patient data patterns, enabling preventive interventions. The COVID-19 pandemic has accelerated digital

health adoption, creating favorable market conditions for innovative monitoring solutions that enhance patient safety while reducing healthcare costs and hospital readmissions.

Threat:

Reimbursement hurdles for newer products and kits

Regulatory agencies require extensive clinical evidence demonstrating cost-effectiveness and safety profiles before approving coverage. Insurance providers often prioritize established treatments over innovative solutions, limiting access to advanced therapeutic options. The lengthy reimbursement approval timeline delays product commercialization and market entry strategies. Moreover, varying reimbursement policies across different regions and healthcare systems complicate global market penetration efforts. These challenges particularly affect emergency injection devices and novel diagnostic kits, potentially hindering innovation adoption and restricting patient access to cutting-edge adrenal crisis management technologies despite their clinical benefits.

Covid-19 Impact:

The COVID-19 pandemic significantly impacted the adrenal crisis management market through disrupted healthcare services and delayed routine monitoring appointments. Patients with adrenal insufficiency faced increased infection vulnerability, necessitating enhanced precautionary measures and stress-dose steroid protocols. Additionally, supply chain disruptions affected medication availability, particularly hydrocortisone products. Telemedicine adoption surged as healthcare providers sought alternative consultation methods, accelerating digital health solution integration. Moreover, the pandemic highlighted the importance of emergency preparedness, driving demand for home-based monitoring devices and self-administration kits for crisis management.

The glucocorticoid therapy segment is expected to be the largest during the forecast period

The glucocorticoid therapy segment is expected to account for the largest market share during the forecast period due to its fundamental role as the primary treatment modality for adrenal insufficiency and crisis prevention. Hydrocortisone remains the gold standard for hormone replacement therapy, with extensive clinical evidence supporting its efficacy and safety profile. Additionally, the segment encompasses various formulations, including oral tablets, injectable solutions, and emergency auto-injectors,

catering to diverse patient needs. The well-established treatment protocols and physician familiarity with glucocorticoid administration contribute to sustained market leadership.

The paediatrics segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the pediatrics segment is predicted to witness the highest growth rate due to increasing recognition and diagnosis of congenital adrenal disorders in children. Early-onset conditions such as congenital adrenal hyperplasia and primary adrenal insufficiency require specialized treatment approaches tailored to pediatric physiology. Additionally, improved neonatal screening programs enable earlier detection, driving demand for age-appropriate therapeutic formulations and monitoring devices. The segment benefits from enhanced awareness among pediatric endocrinologists and primary care physicians regarding adrenal crisis recognition. Moreover, growing parental awareness and advocacy for comprehensive pediatric adrenal care further accelerates segment expansion.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share through advanced healthcare infrastructure, comprehensive insurance coverage, and robust pharmaceutical research capabilities. The region benefits from established endocrinology treatment centers and specialized adrenal insufficiency clinics providing expert patient care. Additionally, strong regulatory frameworks ensure product quality and safety while facilitating innovation adoption. High healthcare expenditure and patient awareness levels support premium treatment options and advanced monitoring technologies. Government initiatives promoting rare disease research and patient advocacy organizations contribute to sustained market growth.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, driven by expanding healthcare infrastructure, increasing diagnostic capabilities, and rising disease awareness among healthcare professionals. Growing economic prosperity enables enhanced healthcare spending and access to advanced therapeutic options. Additionally, government initiatives promoting healthcare accessibility and insurance coverage expansion facilitate market penetration. The region benefits from a large patient population and improving epidemiological surveillance systems for

endocrine disorders. Rising physician training programs in endocrinology and emergency medicine enhance crisis recognition and management capabilities. The digital health technology adoption and telemedicine integration further support rapid market expansion across diverse Asia Pacific healthcare systems.

Key players in the market

Some of the key players in Adrenal Crisis Management Market include Eton Pharmaceuticals, Takeda, Pfizer, Antares Pharma, Sandoz, Halozyme, Novartis, Teva, GSK, AbbVie, Mylan, Ferring, Hikma, Sun Pharma, Cipla, Sanofi, Bayer, AstraZeneca, Amneal, and Endo International.

Key Developments:

In July 2025, Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, has launched Morphine Sulfate Injection, USP, in 2mg/mL and 4mg/mL doses in the US. The product has been launched in a prefilled syringe form and is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

In January 2022, Antares Pharma, Inc. a specialty pharmaceutical company, today announced positive results from a Phase I study for ATRS-1902 for adrenal crisis. The positive results support the advancement of the ATRS-1902 development program to a pivotal clinical study for the treatment of acute adrenal insufficiency, known as adrenal crisis, in adults and adolescents, using our Vai™ novel proprietary rescue pen platform to deliver a liquid stable formulation of hydrocortisone.

In June 2021, Eton Pharmaceuticals, Inc the U.S. marketer of ALKINDI SPRINKLE®, a treatment for adrenocortical insufficiency in pediatric patients, today announced that it has acquired U.S. and Canadian rights to Crossject's ZENEO® hydrocortisone needleless autoinjector, which is under development as a rescue treatment for adrenal crisis.

Treatment Types Covered:

Glucocorticoid Therapy

Mineralocorticoid Therapy (Fludrocortisone)

Fluid & Electrolyte Replacement Therapy

Adjunctive Therapies

Route of Administrations:

Intravenous (IV)

Intramuscular (IM)

Oral

Subcutaneous

Patient Groups Covered:

Adults

Pediatrics

Geriatrics

Neonates

Distribution Channels Covered:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Specialty Drug Distributors

End Users Covered:

Hospitals

Emergency Care Centers

Specialty Clinics

Home Care Settings

Ambulatory Surgical Centers

Other End Users

Regions Covered:

North America

US

Canada

Mexico

Europe

Germany

UK

Italy

France

Spain

Rest of Europe

Asia Pacific

Japan

China

India

Australia

New Zealand

South Korea

Rest of Asia Pacific

South America

Argentina

Brazil

Chile

Rest of South America

Middle East & Africa

Saudi Arabia

UAE

Qatar

South Africa

Rest of Middle East & Africa

What our report offers:

- Market share assessments for the regional and country-level segments

- Strategic recommendations for the new entrants
- Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling

Comprehensive profiling of additional market players (up to 3)

SWOT Analysis of key players (up to 3)

Regional Segmentation

Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)

Competitive Benchmarking

Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Contents

1 EXECUTIVE SUMMARY

2 PREFACE

- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
 - 2.4.1 Data Mining
 - 2.4.2 Data Analysis
 - 2.4.3 Data Validation
 - 2.4.4 Research Approach
- 2.5 Research Sources
 - 2.5.1 Primary Research Sources
 - 2.5.2 Secondary Research Sources
 - 2.5.3 Assumptions

3 MARKET TREND ANALYSIS

- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 End User Analysis
- 3.7 Emerging Markets
- 3.8 Impact of Covid-19

4 PORTERS FIVE FORCE ANALYSIS

- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry

5 GLOBAL ADRENAL CRISIS MANAGEMENT MARKET, BY TREATMENT TYPE

- 5.1 Introduction
- 5.2 Glucocorticoid Therapy
 - 5.2.1 Hydrocortisone (IV/IM)
 - 5.2.2 Dexamethasone
 - 5.2.3 Other Glucocorticoids
- 5.3 Mineralocorticoid Therapy (Fludrocortisone)
- 5.4 Fluid & Electrolyte Replacement Therapy
- 5.5 Adjunctive Therapies

6 GLOBAL ADRENAL CRISIS MANAGEMENT MARKET, BY ROUTE OF ADMINISTRATION

- 6.1 Introduction
- 6.2 Intravenous (IV)
- 6.3 Intramuscular (IM)
- 6.4 Oral
- 6.5 Subcutaneous

7 GLOBAL ADRENAL CRISIS MANAGEMENT MARKET, BY PATIENT GROUP

- 7.1 Introduction
- 7.2 Adults
- 7.3 Pediatrics
- 7.4 Geriatrics
- 7.5 Neonates

8 GLOBAL ADRENAL CRISIS MANAGEMENT MARKET, BY DISTRIBUTION CHANNEL

- 8.1 Introduction
- 8.2 Hospital Pharmacies
- 8.3 Retail Pharmacies
- 8.4 Online Pharmacies
- 8.5 Specialty Drug Distributors

9 GLOBAL ADRENAL CRISIS MANAGEMENT MARKET, BY END USER

- 9.1 Introduction

- 9.2 Hospitals
- 9.3 Emergency Care Centers
- 9.4 Specialty Clinics
- 9.5 Home Care Settings
- 9.6 Ambulatory Surgical Centers
- 9.7 Other End Users

10 GLOBAL ADRENAL CRISIS MANAGEMENT MARKET, BY GEOGRAPHY

- 10.1 Introduction
- 10.2 North America
 - 10.2.1 US
 - 10.2.2 Canada
 - 10.2.3 Mexico
- 10.3 Europe
 - 10.3.1 Germany
 - 10.3.2 UK
 - 10.3.3 Italy
 - 10.3.4 France
 - 10.3.5 Spain
 - 10.3.6 Rest of Europe
- 10.4 Asia Pacific
 - 10.4.1 Japan
 - 10.4.2 China
 - 10.4.3 India
 - 10.4.4 Australia
 - 10.4.5 New Zealand
 - 10.4.6 South Korea
 - 10.4.7 Rest of Asia Pacific
- 10.5 South America
 - 10.5.1 Argentina
 - 10.5.2 Brazil
 - 10.5.3 Chile
 - 10.5.4 Rest of South America
- 10.6 Middle East & Africa
 - 10.6.1 Saudi Arabia
 - 10.6.2 UAE
 - 10.6.3 Qatar
 - 10.6.4 South Africa

10.6.5 Rest of Middle East & Africa

11 KEY DEVELOPMENTS

11.1 Agreements, Partnerships, Collaborations and Joint Ventures

11.2 Acquisitions & Mergers

11.3 New Product Launch

11.4 Expansions

11.5 Other Key Strategies

12 COMPANY PROFILING

12.1 Eton Pharmaceuticals

12.2 Takeda Pharmaceutical Company Limited

12.3 Pfizer Inc.

12.4 Antares Pharma

12.5 Sandoz International GmbH

12.6 Halozyme Therapeutics

12.7 Novartis AG

12.8 Teva Pharmaceutical Industries Ltd.

12.9 GlaxoSmithKline plc

12.10 AbbVie Inc.

12.11 Mylan N.V.

12.12 Ferring Pharmaceuticals

12.13 Hikma Pharmaceuticals

12.14 Sun Pharmaceutical Industries Ltd.

12.15 Cipla Ltd.

12.16 Sanofi S.A.

12.17 Bayer AG

12.18 AstraZeneca plc

12.19 Amneal Pharmaceuticals

12.20 Endo International plc

List Of Tables

LIST OF TABLES

Table 1 Global Adrenal Crisis Management Market Outlook, By Region (2024-2032) (\$MN)

Table 2 Global Adrenal Crisis Management Market Outlook, By Treatment Type (2024-2032) (\$MN)

Table 3 Global Adrenal Crisis Management Market Outlook, By Glucocorticoid Therapy (2024-2032) (\$MN)

Table 4 Global Adrenal Crisis Management Market Outlook, By Hydrocortisone (IV/IM) (2024-2032) (\$MN)

Table 5 Global Adrenal Crisis Management Market Outlook, By Dexamethasone (2024-2032) (\$MN)

Table 6 Global Adrenal Crisis Management Market Outlook, By Other Glucocorticoids (2024-2032) (\$MN)

Table 7 Global Adrenal Crisis Management Market Outlook, By Mineralocorticoid Therapy (Fludrocortisone) (2024-2032) (\$MN)

Table 8 Global Adrenal Crisis Management Market Outlook, By Fluid & Electrolyte Replacement Therapy (2024-2032) (\$MN)

Table 9 Global Adrenal Crisis Management Market Outlook, By Adjunctive Therapies (2024-2032) (\$MN)

Table 10 Global Adrenal Crisis Management Market Outlook, By Route of Administration (2024-2032) (\$MN)

Table 11 Global Adrenal Crisis Management Market Outlook, By Intravenous (IV) (2024-2032) (\$MN)

Table 12 Global Adrenal Crisis Management Market Outlook, By Intramuscular (IM) (2024-2032) (\$MN)

Table 13 Global Adrenal Crisis Management Market Outlook, By Oral (2024-2032) (\$MN)

Table 14 Global Adrenal Crisis Management Market Outlook, By Subcutaneous (2024-2032) (\$MN)

Table 15 Global Adrenal Crisis Management Market Outlook, By Patient Group (2024-2032) (\$MN)

Table 16 Global Adrenal Crisis Management Market Outlook, By Adults (2024-2032) (\$MN)

Table 17 Global Adrenal Crisis Management Market Outlook, By Pediatrics (2024-2032) (\$MN)

Table 18 Global Adrenal Crisis Management Market Outlook, By Geriatrics (2024-2032)

(\$MN)

Table 19 Global Adrenal Crisis Management Market Outlook, By Neonates (2024-2032)

(\$MN)

Table 20 Global Adrenal Crisis Management Market Outlook, By Distribution Channel (2024-2032) (\$MN)

Table 21 Global Adrenal Crisis Management Market Outlook, By Hospital Pharmacies (2024-2032) (\$MN)

Table 22 Global Adrenal Crisis Management Market Outlook, By Retail Pharmacies (2024-2032) (\$MN)

Table 23 Global Adrenal Crisis Management Market Outlook, By Online Pharmacies (2024-2032) (\$MN)

Table 24 Global Adrenal Crisis Management Market Outlook, By Specialty Drug Distributors (2024-2032) (\$MN)

Table 25 Global Adrenal Crisis Management Market Outlook, By End User (2024-2032) (\$MN)

Table 26 Global Adrenal Crisis Management Market Outlook, By Hospitals (2024-2032) (\$MN)

Table 27 Global Adrenal Crisis Management Market Outlook, By Emergency Care Centers (2024-2032) (\$MN)

Table 28 Global Adrenal Crisis Management Market Outlook, By Specialty Clinics (2024-2032) (\$MN)

Table 29 Global Adrenal Crisis Management Market Outlook, By Home Care Settings (2024-2032) (\$MN)

Table 30 Global Adrenal Crisis Management Market Outlook, By Ambulatory Surgical Centers (2024-2032) (\$MN)

Table 31 Global Adrenal Crisis Management Market Outlook, By Other End Users (2024-2032) (\$MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

I would like to order

Product name: Adrenal Crisis Management Market Forecasts to 2032 – Global Analysis By Treatment Type (Glucocorticoid Therapy, Mineralocorticoid Therapy, Fluid & Electrolyte Replacement Therapy and Adjunctive Therapies), Route of Administration (Intravenous, Intramuscular, Oral and Subcutaneous), Patient Group, Distribution Channel, End User and By Geography

Product link: <https://marketpublishers.com/r/AA4F37ED46F2EN.html>

Price: US\$ 4,150.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AA4F37ED46F2EN.html>